Press Release: Research and Markets
DUBLIN–(BUSINESS WIRE)– Research and Markets(http://www.researchandmarkets.com/research/84b62c/morocco_pharmaceut) has announced the addition of the “Morocco Pharmaceuticals and Healthcare Report Q1 2012” report to their offering.
Business Monitor International’s Morocco Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Morocco’s pharmaceuticals and healthcare industry.
BMI View:
According to the figures provided by l’Association Marocaine de l’Industrie Pharmaceutique (AMIP), drug expenditure in Morocco reached a value of MAD9.00bn (US$1.14bn) in 2010. Factors such as the roll-out of the RAMED insurance scheme and the encouragement of generic drug consumptionare expected to shape the market in the coming years. BMI envisages the market posting a compound annual growth rate (CAGR) of 9.3% between 2010 and 2015, as calculated in local currency terms, although per capita spending on medicines will remain suboptimal.
In the meantime, the export of pharmaceuticals from Morocco is expected to continue increasing steadily, facilitated by the country’s strategic location as a manufacturing hub for North Africa’s frontier emerging markets and the less penetrable sub-Saharan Africa region.
Headline Expenditure Projections: Pharmaceuticals: MAD9.00bn (US$1.14bn) in 2010 to MAD9.59bn (US$1.15bn) in 2011; +6.5% in local currency terms and +0.3% in US dollar terms. Forecast down slightly from Q411, despite upward revision of historical data based on new import data.
Healthcare: MAD43.09bn (US$5.47bn) in 2010 to MAD47.20bn (US$5.64bn) in 2011; +9.5% in local currency terms and +3.1% in US dollar terms. Forecast down slightly from Q411 due macroeconomic factors.
Medical devices: MAD2.01bn (US$255mn) in 2010 to MAD2.26bn (US$270mn) in 2011; +12.4% in local currency terms and +5.8% in US dollar terms. Forecast up from Q411 due to upward revision of historical share of medical devices within healthcare spending.
Key Topics Covered By “Morocco Pharmaceuticals and Healthcare Report Q1 2012“:
- SWOT Analysis
- Pharmaceutical Business Environment Ratings
- Industry Forecast Scenario
- Competitive Landscape
- Company Profiles
- Country Snapshot: Morocco Demographic Data
Companies Mentioned:
- GlaxoSmithKline
- Laprophan
- Pfizer
- Promopharm
- Sanofi-Aventis
- Sothema
REASONS TO BUY
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Morocco to test other views – a key input for successful budgeting and strategic business planning in the Morocco pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Morocco Pharmaceutical and Healthcare Sector through its reviews – and major deals, projects and investments in Morocco.
- Exploit The Latest Competitive Morocco Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Morocco.
For more information visithttp://www.researchandmarkets.com/research/84b62c/morocco_pharmaceut
Contact:
Research and Markets
Laura Wood, Senior Manager,
press
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
